Value-Based Cardiology


The study found that avoiding 3 key risk factors—diabetes, obesity, and hypertension—by age 45, greatly increased the likelihood of avoiding heart failure through the end of life.
The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
High doses of the antidepressants citalopram (Celexa) and escitalopram (Cipralex, Lexapro) do not appear to carry greater risk of sudden cardiac death than comparable doses of other selective serotonin reuptake inhibitors, according to a new study.
A pilot analysis published online in JAMA Cardiology has concluded that Twitter offers promise as a data source for studying public communication about cardiovascular disease.
The Jackson Heart Study continues to yield insights about the nature of cardiovascular disease in minority populations.


July 25-27, 2015
Vancouver, BC, Canada
August 14-16, 2015
Mackinac Island,MI
Diabetes Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium